Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21768429 | 0.81 | DGAT1 (0.40) | DGAT1MAPTNPC1 | |
| SCHEMBL22803885 | 0.81 | NPC1 (0.33) | KDM1ADGAT1NPC1 | |
| SCHEMBL15058389 | 0.80 | MAPT (0.36) | DGAT1MAPTNPC1 | |
| SCHEMBL15102134 | 0.80 | MAPT (0.35) | DGAT1MAPTNPC1 | |
| SCHEMBL15058604 | 0.79 | DGAT1 (0.34) | DGAT1MAPTNPC1 | |
| SCHEMBL16611671 | 0.77 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL15058090 | 0.75 | MAPT (0.35) | DGAT1MAPTNPC1 | |
| SCHEMBL101482 | 0.75 | DGAT1 (0.33) | KDM1ADGAT1MAPTNPC1 | |
| SCHEMBL11318913 | 0.75 | BRD4 (0.34) | DGAT1 | |
| SCHEMBL565470 | 0.75 | KDM4E (0.34) | KDM1ADGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794605-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | KDM1A 1888/4885DGAT1 4694/4885MAPT 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.